Private vs Public: Privacy in Trials

There was quite a ruckus in the cancer drug development community when Memorial Sloan Kettering Cancer Center (MSKCC) suspended enrollment in three trials of therapies based on chimeric antigen receptor (CAR) technology. The news came from Twitter, where Jonah Lomu shared the following: Aside from the science/clinical aspect, I thought the “news” and subsequent unfolding of the story […]

Read More

Biotechnology & Madison High Schools

At the Biotech in WI Meetup this week, we learned about the Biotechnology elective at West, Memorial and La Follette high schools in Madison. Lisa Wachtel, Science Coordinator for Madison Metropolitan School District (MMSD), provide background about one of the hands-on laboratory opportunities available during the school day. MMSD Biotechnology Program Needs Although the discussion […]

Read More

R&D Scientists: Welcome to Your Contract

This tweet recently caught my eye. (I’m assuming pharma here is drug related, including biotech.) We’ve certainly heard about the R&D cutbacks in pharma and lean/backyard/virtual biotech companies need their work done somewhere. But 2/3 of pharma R&D is to be done by outside labs?! One reason I was caught off guard is my own […]

Read More

Walking the Walk: Stories of Drug Development

When I first started writing here in 2011, I thought that the time was near for the biotech industry to adopt the social media tools that the tech venture capitalists and entrepreneurs were using to talk about their investment strategies, product launches, development strategies, etc.* At the end of 2013, I considered telling the story […]

Read More

Partnering Tidbits from Turin

I’ve escaped the cube farm long enough to share a few thoughts from BIO-Europe Spring in Turin. Quality vs. Quantity Finding the sweet spot between busy and busy work at a partnering conference can be a challenge. The theoretical benefit to casting a wide net is that you are more likely to catch someone’s interest. […]

Read More

Personal Risk & Social Media in Pharma/Biotech

Benefit: Something that promotes or enhances well-being Risk: the possibility of suffering harm or loss While there is a growing group of pharma/biotech professionals engaging via social media, most people I know believe the risks vastly outweigh the benefits. Working in a risk averse culture with a low social media adoption rate may result in […]

Read More

Weekend Reading List 2/15/14

Inspired by the Biotech Reading List over at BioDueDiligence, I thought I would share a few items from my weekend reading list. Over at the Kauffman Foundation, there is a new report out called Declining Business Dynamism in the US High-Technology Sector that includes in the conclusion “This sector typically is viewed as very entrepreneurial, but we […]

Read More

Is Biotech Venture Capital Dying?

This post was inspired by the Xconomy story Wisconsin 2013 VC Activity Drops, Shifts to Software from Biotech. To recap, Wisconsin has historically fared very poorly by virtually any measure related to venture capital. And 2013 was ugly form a numbers perspective: VC funding in the state dropped from $95.3M in 2012 to $35.9M. (Here’s […]

Read More

Social Media & Cancer Drugs: Conversation, not Promotion

*This post was originally posted at Xconomy.* (Updated to include Lilly COI in table based on comment below.) Social media hasn’t yet changed the world for biotech and pharma companies, but I believe this year is the year that will change. For better or worse, these tools change the way people can communicate about specific things […]

Read More

#JPM14 Mad Libs

Here is a short JP Morgan Themed Mad Libs to keep you entertained between meetings. Hat tip to Brian Reid and his list of buzzwords for the extra push to post. I’m  (NAME) the (ADJECTIVE) and I am (DREAM JOB TITLE) at a biotech company with a drug candidate to treat (DISEASE), which is an […]

Read More
Follow

Get every new post delivered to your Inbox.

Join 64 other followers